Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration

BACKGROUND: Sasanlimab is a monoclonal antibody that binds to the programmed cell death receptor 1 (PD-1). Anti-PD-1 monoclonal antibodies have improved patient clinical outcomes; however, not all treated patients derive clinical benefit. Further insights on potential biomarkers beyond PD-L1 express...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu-Lieskovan, Siwen, Braiteh, Fadi, Grilley-Olson, Juneko E., Wang, Xiao, Forgie, Alison, Bonato, Vinicius, Jacobs, Ira A., Chou, Jeffrey, Johnson, Melissa L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613140/
https://www.ncbi.nlm.nih.gov/pubmed/34694529
http://dx.doi.org/10.1007/s11523-021-00833-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613140/
https://www.ncbi.nlm.nih.gov/pubmed/34694529
http://dx.doi.org/10.1007/s11523-021-00833-2

Ejemplares similares